JP2009529906A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529906A5
JP2009529906A5 JP2009500939A JP2009500939A JP2009529906A5 JP 2009529906 A5 JP2009529906 A5 JP 2009529906A5 JP 2009500939 A JP2009500939 A JP 2009500939A JP 2009500939 A JP2009500939 A JP 2009500939A JP 2009529906 A5 JP2009529906 A5 JP 2009529906A5
Authority
JP
Japan
Prior art keywords
fusion protein
polypeptide
protein according
receptor
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529906A (ja
Filing date
Publication date
Priority claimed from GBGB0605735.0A external-priority patent/GB0605735D0/en
Application filed filed Critical
Publication of JP2009529906A publication Critical patent/JP2009529906A/ja
Publication of JP2009529906A5 publication Critical patent/JP2009529906A5/ja
Pending legal-status Critical Current

Links

JP2009500939A 2006-03-22 2007-03-22 免疫応答を調節するための組成物および方法 Pending JP2009529906A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0605735.0A GB0605735D0 (en) 2006-03-22 2006-03-22 Composition and method for mediating an immune response
PCT/GB2007/050143 WO2007107797A2 (en) 2006-03-22 2007-03-22 Fusion protein comprising an fc receptor binding polypeptide and an antigenic polypeptide for mediating an immune response

Publications (2)

Publication Number Publication Date
JP2009529906A JP2009529906A (ja) 2009-08-27
JP2009529906A5 true JP2009529906A5 (https=) 2011-08-18

Family

ID=36383953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009500939A Pending JP2009529906A (ja) 2006-03-22 2007-03-22 免疫応答を調節するための組成物および方法

Country Status (6)

Country Link
US (2) US20090186025A1 (https=)
EP (1) EP2007807A2 (https=)
JP (1) JP2009529906A (https=)
CN (2) CN101448854A (https=)
GB (1) GB0605735D0 (https=)
WO (1) WO2007107797A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615266D0 (en) * 2006-08-01 2006-09-06 Immunobiology Ltd Composition and method for mediating an immune response
EP2450368A1 (en) 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
TWI422594B (zh) * 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑
MX2009008926A (es) * 2007-02-23 2009-09-14 Baylor Res Inst Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
US9592287B2 (en) 2009-10-09 2017-03-14 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
BR112015001390B1 (pt) 2012-07-26 2024-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina
WO2015175957A1 (en) 2014-05-16 2015-11-19 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽,其组合物、制备方法以及用途
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术(上海)有限公司 一种新的重组双功能融合蛋白及其制备和应用
CN106366179A (zh) * 2016-08-28 2017-02-01 苏州普罗达生物科技有限公司 一种跨膜硫酸乙酰肝泰蛋白多糖1免疫激动剂多肽及其用途
CN106366180A (zh) * 2016-08-28 2017-02-01 苏州普罗达生物科技有限公司 一种上皮生长因子受体免疫原多肽及其用途
CN106337040A (zh) * 2016-08-28 2017-01-18 苏州普罗达生物科技有限公司 一种内皮细胞受体蛋白酪氨酸激酶a2免疫原多肽及其用途
US20220073630A1 (en) * 2018-12-28 2022-03-10 Hoffmann-La Roche, Inc. A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
CN110093360B (zh) * 2019-04-15 2021-06-15 华南农业大学 一种表达Fc片段的狂犬病病毒G蛋白的融合蛋白及其制备方法
CN112870344B (zh) * 2019-11-29 2022-07-19 北京绿竹生物技术股份有限公司 一种重组水痘带状疱疹病毒疫苗
CN110872358B (zh) * 2019-12-04 2021-12-10 天康制药(苏州)有限公司 HA-Fc融合蛋白及其制备方法和疫苗
CA3211083A1 (en) * 2021-03-04 2022-09-09 Kyle BACKMAN Compositions including sbi adjuvants and methods of use thereof
CN116769014A (zh) * 2023-06-07 2023-09-19 河南省农业科学院动物免疫学重点实验室 一种牛IgG Fc受体boFcγRI的线性配体结合表位
WO2026030592A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use
CN119841940B (zh) * 2025-03-19 2025-06-20 中国人民解放军军事科学院军事医学研究院 一种抗基孔肯雅病毒e蛋白的纳米抗体n033及其应用
CN121021646B (zh) * 2025-10-31 2026-01-09 西北农林科技大学深圳研究院 猪抗原提呈细胞靶向肽及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
ATE204300T1 (de) * 1994-05-13 2001-09-15 Biovation Ltd Zielzellen-bindende chimäre peptide
US6391589B1 (en) * 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
AU5090899A (en) * 1998-07-06 2000-01-24 University Of Tennessee Research Corporation, The Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE355374T1 (de) * 2000-11-27 2006-03-15 Praecis Pharm Inc Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens

Similar Documents

Publication Publication Date Title
JP2009529906A5 (https=)
Nguyen et al. Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons
JP6882184B2 (ja) 多価b型肝炎ウイルス抗原結合分子およびその使用
Park et al. Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells
HRP20210876T1 (hr) Anti-tmprss2 antitijela i fragmenti koji vezuju antigen
JP2021508449A5 (https=)
JP2017527272A5 (https=)
KR102706285B1 (ko) 항 인터페론 감마 항체 및 그의 용도
AU2015206002B2 (en) Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen
JP6050747B2 (ja) インフルエンザ受動免疫化に有用な抗体
US10654915B2 (en) Antibodies useful in passive influenza immunization
JP2010521147A5 (https=)
JP2011509245A5 (https=)
JP2016512213A5 (https=)
JP2010502207A5 (https=)
CA2963470A1 (en) Antibodies that bind ebola glycoprotein and uses thereof
RU2016129724A (ru) Антитела, содержащие с-концевые удлинения полипептида легкой цепи, их конъюгаты и способы применения
JP2017534296A5 (https=)
Mendoza et al. Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rγc KO. NOD)
US20230293652A1 (en) Immunostimulatory adjuvants
RU2016135962A (ru) Выделенное антитело, способ его получения, выделенная нуклеиновая кислота, экспрессионная кассета, клетка-хозяин, фармацевтический и диагностический препараты, способ лечения больного, подверженного риску или страдающего от инфекции E.COLI, и способ диагностики определения инфекций E.COLI
King et al. Achieving cross-reactivity with pan-ebolavirus antibodies
JP2019511457A5 (https=)
JP2018537117A5 (https=)
Zhang et al. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus